MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
Cyclacel Pharmaceuticals Cash and Cash Equivalents 2011-2026 | CYCC
Annual Cash and Cash Equivalents Cyclacel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.5 M | 3.14 M | 3.38 M | 18.3 M | 36.6 M | 33.4 M | 11.9 M | 17.5 M | 23.9 M | 16.5 M | 20.4 M | 24.2 M | 31.1 M | 16.4 M | 24.4 M | 29.5 M | 11.5 M | 24.2 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.6 M | 3.14 M | 19.4 M |
Quarterly Cash and Cash Equivalents Cyclacel Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.34 M | 3.84 M | 4.28 M | 3.45 M | 3.14 M | 2.98 M | 6 M | 2.8 M | 3.38 M | 5.94 M | 10.2 M | 11.4 M | 18.3 M | 23.7 M | 29.1 M | 29.6 M | 36.6 M | 40.2 M | 43.6 M | 47.8 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.8 M | 2.8 M | 20.2 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
261 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | USA |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
43.9 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
21.3 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B |  Britain |
 |
CureVac N.V.
CVAC
|
482 M | - | - | $ 867 M | Germany |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.36 | -4.23 % | $ 159 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
89 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
38.5 M | - | -34.95 % | $ 21.5 M | Germany |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 49.44 | -3.96 % | $ 4.45 B |  Schweiz |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
12.4 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
28.9 M | $ 29.35 | -0.84 % | $ 1.95 B | USA |
 |
Generation Bio Co.
GBIO
|
76.3 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
21.2 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.89 M | $ 0.67 | -2.89 % | $ 30.6 M | Israel |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 3.14 | - | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 30.95 | 1.38 % | $ 833 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
47.3 M | - | - | $ 384 M | Britain |
 |
Exelixis
EXEL
|
482 M | $ 52.58 | -0.77 % | $ 14.3 B | USA |
 |
Gracell Biotechnologies
GRCL
|
1.45 B | - | - | $ 3.37 B | China |
|
Forte Biosciences
FBRX
|
77 M | $ 16.82 | -1.06 % | $ 218 M | USA |
 |
Anika Therapeutics
ANIK
|
57.5 M | $ 14.95 | 2.57 % | $ 214 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.53 M | $ 2.82 | -3.09 % | $ 4.64 M | Israel |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |